Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test

#354

Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.

Aim(s): We evaluated OT prognostic value in a prospective cohort of patients.

Materials and methods: From January 2008 to June 2010 we prospectively evaluated 44 GEP-NET patients, undergoing OT with plasma CgA determination at 0, 3, 6 hours. SSAs were given by monitoring clinical outcome.

Conference:

Presenting Author:

Authors: Rossi R, Massironi S, Spampatti M, Conte D, Ciafardini C,

Keywords: octreotide test, somatostatin analogs,

To read the full abstract, please log into your ENETS Member account.